Dextromethorphan hydrobromide remains one of the most widely used active ingredients in over-the-counter cough syrups, but recent news highlights several important updates regarding safety, recalls, and regulatory scrutiny as of 2025.
Latest Recalls and Safety Alerts

• In January and February 2025, several batches of dextromethorphan hydrobromide BP-containing cough syrups were recalled by Bells Healthcare in the UK due to precautionary concerns, specifically the presence of foreign material and quality issues.
• Both the Medicines and Healthcare products Regulatory Agency (MHRA) and related safety bulletins have stressed the need for healthcare professionals to review product safety, and consumers are advised to check for recent recall notices.

Regulatory Status and Updates

• In August 2025, the European Medicines Agency (EMA) completed a detailed safety update for combination medications containing dextromethorphan hydrobromide, indicating ongoing regulatory oversight and periodic reassessment of risks and benefits.
• In India, the CDSCO recently banned 35 unapproved Fixed Dose Combinations (FDCs) in April 2025, tightening scrutiny, though dextromethorphan monotherapy remains in general use. Providers are now under stricter reporting guidelines regarding cough syrup compositions.

Clinical Use and Concerns

• Dextromethorphan is generally well tolerated at recommended antitussive doses (15–30 mg per dose, up to 4 times daily), but it should not be used in children under four years old due to insufficient safety data and risk of toxicity.
• Abuse and overdose risks remain a significant concern, especially in adolescents and young adults. High doses can cause neuropsychiatric effects, including agitation, hallucinations, and, in severe cases, coma or death. Poison control recommends vigilance regarding misuse patterns and accidental ingestion.

Summary Table: Key 2025 Updates

Aspect	Details (2025)
Major Recalls	Bells Healthcare cough syrups (UK, Jan–Feb 2025)
Regulatory Updates	EMA safety reassessment; India bans select FDCs
Pediatric Use	Not recommended under age 4
Abuse Risk	High doses cause serious side effects; growing concern

 
Dextromethorphan hydrobromide cough syrup continues to be widely available, but ongoing recalls and reinforced safety guidance mean prescribers and consumers should monitor for regulatory changes and updated recommendations.

Download Pdf